Abstract
Rational drug design method has been used to generate 4-arylpiperazine carboxamides in an effort to develop safer, more potent and effective monoamine neurotransmitters reuptake inhibitors. Out of twenty-seven synthesized compounds, compound 9 displayed potent monoamine neurotransmitter reuptake inhibitory activity against HEK cells transfected with hSERT or hNET. A Surflex-Dock docking model of 9 was also studied.
Keywords:
4-Arylpiperazine carboxamide; Docking; Norepinephrine reuptake inhibitor; Serotonin reuptake inhibitor.
Copyright © 2018. Published by Elsevier Ltd.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Dose-Response Relationship, Drug
-
Drug Design*
-
HEK293 Cells
-
Humans
-
Molecular Docking Simulation
-
Molecular Structure
-
Neurotransmitter Uptake Inhibitors / chemical synthesis
-
Neurotransmitter Uptake Inhibitors / chemistry
-
Neurotransmitter Uptake Inhibitors / pharmacology*
-
Norepinephrine Plasma Membrane Transport Proteins / antagonists & inhibitors*
-
Norepinephrine Plasma Membrane Transport Proteins / metabolism
-
Piperazine / chemical synthesis
-
Piperazine / chemistry
-
Piperazine / pharmacology*
-
Serotonin Plasma Membrane Transport Proteins / metabolism*
-
Structure-Activity Relationship
Substances
-
Neurotransmitter Uptake Inhibitors
-
Norepinephrine Plasma Membrane Transport Proteins
-
Serotonin Plasma Membrane Transport Proteins
-
Piperazine